Skip to main content
SpringerLink
Log in

Pramipexole in Routine Clinical Practice

A Prospective Observational Trial in Parkinson’s Disease

  • Original Research Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Objective: The mixed dopamine D2/D3 receptor agonist pramipexole is effective as monotherapy in early Parkinson’s disease and as adjunctive therapy in advanced disease. Clinical trials suggest that the benefits of pramipexole may extend beyond the relief of motor symptoms (akinesia, rigidity and tremor at rest) to amelioration of depressive symptoms in Parkinson’s disease. The aim of this study was to confirm the beneficial effects of pramipexole on the core symptoms of Parkinson’s disease (with a focus on tremor), as well as to assess its antidepressant activity, during routine clinical practice. The study also aimed to demonstrate the practicability of the Snaith-Hamilton Pleasure Scale (SHAPS-D), the Tremor Impact Scale (TIS) and the Short Parkinson’s Evaluation Scale (SPES) under conditions of routine clinical practice.

Study design: This was a prospective observational study.

Patients: Data for 657 outpatients with Parkinson’s disease were collected from German hospitals and specialist practices. The majority of patients were in Hoehn & Yahr stage II or III and were receiving levodopa.

Methods: Pramipexole (Sifrol®) was initiated at a dosage of 0.375 mg/day (using a three-times-daily schedule) and titrated upwards, as required, at weekly intervals over a 4-week period to a maximum dosage of 4.5 mg/day (three times daily). Clinical evaluation was performed at baseline, at the end of the titration phase and at the end of maintenance therapy. Patients were assessed via the German questionnaire versions of the physician-assessed SPES, the self-evaluated TIS and the SHAPS-D. Changes in scale scores were evaluated nonparametrically, using the Wilcoxon-matched pairs test. Crombach’s α was used as a measure for item consistency.

Results: Pramipexole significantly improved SPES subscores for motor symptoms, complications of therapy, psychological status and activities of daily living. Pramipexole also reduced the detrimental effect of tremor on activities of daily living and social interactions, as assessed by patients via the TIS. As indicated by the results of the SHAPS-D questionnaire, pramipexole significantly reduced anhedonia in patients who had associated depression. Internal consistency of SPES subscales was found to be unaltered between the initial evaluation and follow-up. Likewise, internal consistency for TIS and SHAPS-D was demonstrated. Pramipexole was well tolerated and accepted by the vast majority of physicians and patients.

Conclusion: In addition to ameliorating the core symptoms of akinesia and rigidity in Parkinson’s disease, pramipexole improves tremor and depressive symptoms in routine clinical practice. The SPES, TIS and SHAPS-D were found to be useful instruments with validity in this study.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of tradenames is for product identification purposes only and does not imply endorsement. Sifrol® is available outside Germany as Mirapex® and Mirapexin®.

References

  1. Clarke CE, Speller JM, Clarke JA. Pramipexole for levodopa-induced complications in Parkinson’s disease [systematic review]. Cochrane Movement Disorders Group. Cochrane Database Syst Rev 2003; 1

  2. Lieberman A, Minagar A, Pinter MM. The efficacy of pramipexole in the treatment of Parkinson’s disease. Rev Contemp Pharmacother 2001; 12: 59–86

    CAS  Google Scholar 

  3. Mierau J, Schneider FJ, Ensinger HA, et al. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol 1995 Jun; 290(1): 29–36

    Article  PubMed  CAS  Google Scholar 

  4. Guttman M, Jaskolka J. The use of pramipexole in Parkinson’s disease: are its actions D(3) mediated? Parkinsonism Relat Disord 2001 Jul; 7(3): 231–4

    Article  PubMed  Google Scholar 

  5. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson’s disease: a randomised dose-ranging study. JAMA 1997 Jul; 278(2): 125–30

    Article  Google Scholar 

  6. Shannon KM, Bennett JP, Friedman JH. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson’s disease. Neurology 1997 Sep; 49(3): 724–8

    Article  PubMed  CAS  Google Scholar 

  7. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000 Oct; 284(15): 1931–8

    Article  Google Scholar 

  8. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson’s disease. Neurology 1997 Oct; 49(4): 1060–5

    Article  PubMed  CAS  Google Scholar 

  9. Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson’s disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology 1997 Jul; 49(1): 162–8

    Article  PubMed  CAS  Google Scholar 

  10. Wermuth L. A double-blind, placebo-controlled, randomized, multicenter study of pramipexole in advanced Parkinson’s disease. Eur J Neurol 1998 May; 5(3): 235–42

    Article  PubMed  Google Scholar 

  11. Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson’s disease: a double-blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry 1999 Apr; 66(4): 436–41

    Article  PubMed  CAS  Google Scholar 

  12. Kunig G, Pogarell O, Moller JC, et al. Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson’s disease. Clin Neuro-pharmacol 1999 Sep–Oct; 22(5): 301–5

    CAS  Google Scholar 

  13. Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson’s disease and marked drug resistant tremor: a randomized, double-blind, placebo-controlled multi-centre study. J Neurol Neurosurg Psychiatry 2002 Jun; 72(6): 713–20

    Article  PubMed  CAS  Google Scholar 

  14. Cummings JL. Depression and Parkinson’s disease: a review. Am J Psychiatry 1992 Apr; 149(4): 443–54

    PubMed  CAS  Google Scholar 

  15. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000; 11(2): 58–65

    Article  PubMed  CAS  Google Scholar 

  16. Kraus PH, Martinez P, Bonicelli U, et al. The Short Parkinson Evaluation Scale (SPES) in routine use in a pramipexole study [abstract]. Mov Disord 2002; 17Suppl. 5: S224

    Google Scholar 

  17. Snaith RP, Hamilton M, Morley S, et al. A scale for the assessment of hedonic tone: the Snaith-Hamilton pleasure scale. Br J Psychiatry 1995 Jul; 167(1): 99–103

    Article  PubMed  CAS  Google Scholar 

  18. Franz M, Lemke MR, Meyer T, et al. Deutsche version der Snaith-Hamilton-Pleasure Scale (SHAPS-D). Fortschr Neurol Psychiatr 1998 Sep; 66(9): 407–13

    Article  PubMed  CAS  Google Scholar 

  19. Lemke MR, Puhl P, Koethe PP, et al. Psychomotor retardation and anhedonia in depression. Acta Psychiatr Scand 1999 Apr; 99(4): 252–6

    Article  PubMed  CAS  Google Scholar 

  20. Bland MJ, Altman DG. Cronbach’s alpha. BMJ 1997 Feb; 314(7080): 572

    Article  PubMed  CAS  Google Scholar 

  21. Rabey JM, Bass H, Bonuccelli U, et al. Evaluation of the short Parkinson’s evaluation scale: a new friendly scale for the evaluation of Parkinson’s disease in clinical drug trials. Clin Neuropharmacol 1997; 20(4): 322–37

    Article  PubMed  CAS  Google Scholar 

  22. Rabey JM, Klein C, Molochnikov A, et al. Comparison of the Unified Parkinson’s Disease Rating Scale and the Short Parkinson’s Evaluation Scale in patients with Parkinson’s disease after levodopa loading. Clin Neuropharmacol 2002 Mar–Apr; 25(2): 83–8

    Article  PubMed  Google Scholar 

  23. Yamamoto M. Depression in Parkinson’s disease: its prevalence, diagnosis and neurochemical background. J Neurol 2001 Sep; 248Suppl. 3: III5–11

    PubMed  Google Scholar 

  24. Snaith RP. Identifying depression: the significance of anhedonia. Hosp Pract (Off Ed) 1993 Sep; 28(9A): 55–60

    CAS  Google Scholar 

  25. Kuopio A-M, Marttila RJ, Helenius H, et al. The quality of life in Parkinson’s disease. Mov Disord 2000 Mar; 15(2): 216–23

    Article  PubMed  CAS  Google Scholar 

  26. Schrag A, Jahanshahi M, Quinn N. What contributes to quality of life in patients with Parkinson’s disease? J Neurol Neurosurg Psychiatry 2000 Sep; 69(3): 308–12

    Article  PubMed  CAS  Google Scholar 

  27. Fibiger HC. The neurobiological substrates of depression in Parkinson’s disease: a hypothesis. Can J Neurol Sci 1984 Feb; 11Suppl. 1: 105–7

    PubMed  CAS  Google Scholar 

  28. Braak H, Braak E. Pathoanatomy of Parkinson’s disease. J Neurol 2000 Apr; 247Suppl. 2: 113–10

    Google Scholar 

  29. Szegedi A, Hillert A, Wetzel H, et al. Pramipexole, a dopamine agonist, in major depression: antidepressant effects and tolerability in an open-label study with multiple doses. Clin Neuropharmacol 1997; 20Suppl. 1: 36–45

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported by Boehringer Ingelheim Pharma GmbH & Co. KG, Germany. H. Reichmann, P.H. Kraus and M.R. Lemke received financial compensation from Boehringer-Ingelheim Pharma GmbH & Co. KG for developing the study concept.

Author information

Authors and Affiliations

  1. Department of Neurology, Technical University of Dresden, Fetscherstraβe 74, Dresden, D-1307, Germany

    Heinz Reichmann

  2. Division of Medicine, Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany

    Michael H. Brecht & Jürgen Köster

  3. Department of Neurology, St. Josef-Hospital, University of Bochum, Bochum, Germany

    Peter H. Kraus

  4. Center for Psychiatry and Neurology, Rhine Clinic, Bonn, Germany

    Mathias R. Lemke

Authors
  1. Heinz Reichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael H. Brecht
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jürgen Köster
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter H. Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mathias R. Lemke
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reichmann, H., Brecht, M.H., Köster, J. et al. Pramipexole in Routine Clinical Practice. CNS Drugs 17, 965–973 (2003). https://doi.org/10.2165/00023210-200317130-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200317130-00003

Keywords

Search

Navigation